Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

ance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the immunologic activity of HspE7 in treating CIN; that we identified an optimal dosing range for Phase 2 development and that our TLR3 agonist may have application in both therapeutic as well as prophylactic vaccines.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that immunologic activity of HspE7 may not treat CIN; the possibility that immunology responses may not be a predictor of clinical or therapeutic benefit; our need for capital; the outcomes of our clinical trials; the possibility that our drug candidate will not treat target diseases as intended; the possibility that we will not be successful in licensing our TLR3 agonist to other vaccine developers; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at '/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained the ... Safety of Regenerative Medicine from the Ministry of Health, Labour ... 29, 2015. The fact that R- ... through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) ... allows it to provide stem cell manufacturing service to medical ...
(Date:6/30/2015)... June 30, 2015  NASA astronaut Kjell Lindgren , ... on his first mission to the International Space Station ... to 9 a.m. EDT Tuesday, July 7. Lindgren ... City, Russia . The interviews will be ... highlighting his mission training. To schedule an interview, ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... does not sacrifice selectivity to achieve faster flow rates in comparison to nylon ... with significant open space to allow easy liquid flow while trapping particulates as ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... , ... Multi-talented IEEE1394b Firewire lab workhorse delivers high resolution and sensitivity , ... Surrey, British Columbia ... easy-to-use digital cameras for life science and industrial applications, has announced the release ...
... , SEATTLE, Aug. 21 Cell Therapeutics, Inc. ... its previously announced sale of $30 million of shares of its ... common stock in a registered offering to a single institutional investor. ... of Series 2 Preferred Stock and to receive the 18,853,103 shares ...
... , , CAPE CANAVERAL, Fla., ... Sunday, Aug. 23, to discuss new science experiments using the International Space ... Center in Florida and will be broadcast live on NASA Television. ... , Media are invited to e-mail questions in advance ...
Cached Biology Technology:QImaging Introduces EXi Aqua™ Microscopy Camera for Bio-Imaging 2QImaging Introduces EXi Aqua™ Microscopy Camera for Bio-Imaging 3Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants 2NASA Sets Briefing on New Space Station Science Experiments 2
(Date:6/15/2015)... June 15, 2015 A new report ... reveals the majority of US consumers using mobile banking applications ... such as fingerprint and voiceprint, instead of having to prove ... to Telstra,s " Mobile Identity   -   The Fusion ... with smartphones now the primary channel used by Gen X ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
(Date:6/9/2015)... 09, 2015 Research and Markets  ( ... "Gesture Recognition & Touchless Sensing Market by ... & Others), Product (Biometric & Sanitary Equipment) & ... report to their offering. The total ... to reach $ 23.55 Billion by 2020 at ...
Breaking Biology News(10 mins):One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... the breakdown of old bone by cells called ... cells called osteoblasts. This coordinated activity is essential ... leads to bone destruction in skeletal diseases such ... bone. A family of signaling enzymes known as ...
... ants and relatives comprise the megadiverse insect order ... group on Earth, far surpassing the number of ... orders of animals (beetles, butterflies, wasps, and true ... complete metamorphosis, i.e. having a dormant pupa, jointly ...
... known for their use in exfoliating skin to soft, radiant ... sustainability efforts on two fronts at the same time: energy ... bacteria to create a power-generating microbial fuel cell (MFC) and ... . Shungui Zhou and colleagues note that MFCs, ...
Cached Biology News:New target identified for preventing bone destruction in diseases such as arthritis and cancer 2Fossils clarify the origins of wasps and their kin: alderfly ancestors, snakefly cousins 2
...
ANTI DIPHTH TOX A SU...
... Bullseye Red Taq DNA Polymerase is a ... high activity in primer extension and other ... red dye which provides easy and quick ... added and allows confirmation of complete mixing. ...
... Methylation-specific PCR (MSP) is a new ... gene methylation utilizing small amounts of ... initial bisulfite reaction to modify the ... specific primers designed to distinguish methylated ...
Biology Products: